News Release Details

MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2023.

Third Quarter 2023 Summary:

• Revenue increased 7% year-over-year to $69.6 million, compared to $65.3 million in third quarter 2022
  • Lymphedema revenue increased 15%
  • Airway clearance revenue decreased 36%
• Operating income of $8.0 million, compared to operating loss of $1.6 million in third quarter 2022
• Net income of $22.3 million, compared to a net loss of $2.3 million in third quarter 2022
• Adjusted EBITDA of $7.7 million, up from $7.2 million in third quarter 2022
• Cash balance of $66.0 million on September 30, 2023, compared to $63.2 million on June 30, 2023
• Updating full year 2023 financial guidance

Third Quarter 2023 Highlights:

• Sherri Ferstler appointed to the position of Senior Vice President of Sales, effective July 31, 2023
• The Company’s existing credit agreement was amended on August 1, 2023 to extend the maturity date and improve terms

Highlights Subsequent to Quarter End:

• Vindell Washington, M.D. appointed to the Company’s Board of Directors, effective October 2, 2023
  

“Our team delivered another quarter of solid financial and operational performance,” said Dan Reuvers, President and Chief Executive Officer of Tactile Medical. “Revenue from our lymphedema products exceeded our expectations, increasing 15% year-over-year, our fourth consecutive quarter of double-digit lymphedema products growth, which more than offset the decrease in revenue from our airway clearance product line. Our total revenue performance and operating leverage – driven by continued improvements in our salesforce productivity and operational efficiency – enabled us to generate record quarterly operating income and increased cash flow from operations.”

Mr. Reuvers continued: “We look forward to bringing 2023 to a strong conclusion as we execute our strategic initiatives and drive continued progress with respect to our multi-year financial goals.”

Third Quarter 2023 Financial Results

Total revenue in the third quarter of 2023 increased $4.3 million, or 6.6%, to $69.6 million, compared to $65.3 million in the third quarter of 2022. The increase in total revenue was attributable to an increase of $8.3 million, or 15.3%, in sales and rentals of the lymphedema product line, which more than offset a $4.0 million, or 35.9%, decrease in sales of the airway clearance product line in the quarter ended September 30, 2023.

Gross profit in the third quarter of 2023 increased $2.6 million, or 5.5%, to $49.4 million, compared to $46.8 million in the third quarter of 2022. Gross margin was 70.9% of revenue, compared to 71.7% of revenue in the third quarter of 2022. Non-GAAP gross margin was 71.4% of revenue, compared to 72.2% of revenue in the third quarter of 2022.

Operating expenses in the third quarter of 2023 decreased $7.0 million, or 14.5%, to $41.4 million, compared to $48.4 million in the third quarter of 2022.

Operating income was $8.0 million in the third quarter of 2023, compared to an operating loss of $1.6 million in the third quarter of 2022. Non-GAAP operating income in the third quarter of 2023 was $5.2 million, compared to non-GAAP operating income of $3.9 million in the third quarter of 2022.

Other expense was $0.4 million in the third quarter of 2023, compared to $0.7 million in the third quarter of 2022.

Income tax benefit was $14.7 million in the third quarter of 2023, compared to $0.1 million in the third quarter of 2022.

Net income in the third quarter of 2023 was $22.3 million, or $0.94 per diluted share, compared to a net loss of $2.3 million, or $0.11 per diluted share, in the third quarter of 2022. Non-GAAP net income in the third quarter of 2023 was $20.2 million, compared to non-GAAP net income of $1.9 million in the third quarter of 2022.

Weighted average shares used to compute diluted net income and loss per share were 23.8 million and 20.1 million for the third quarters of 2023 and 2022, respectively.

Adjusted EBITDA was $7.7 million in the third quarter of 2023, compared to $7.2 million in the third quarter of 2022.

First Nine Months 2023 Financial Results

Total revenue for the nine months ended September 30, 2023, increased $23.9 million, or 13.8%, to $196.8 million, compared to $172.9 million for the nine months ended September 30, 2022. The increase in revenue was attributable to an increase of $25.8 million, or 17.6%, in sales and rentals of the lymphedema product line, which more than offset a $1.9 million, or 7.1%, decrease in sales of the airway clearance product line for the nine months ended September 30, 2023.

Net income for the nine months ended September 30, 2023, was $20.3 million, or $0.88 per diluted share, compared to a net loss of $22.5 million, or $1.12 per diluted share, for the nine months ended September 30, 2022. Non-GAAP net income for the nine months ended September 30, 2023, was $20.6 million, compared to a non-GAAP net loss of $9.5 million for the nine months ended September 30, 2022.

Weighted average shares used to compute diluted net income or loss per share were 23.0 million and 20.0 million for the nine months ended September 30, 2023 and 2022, respectively.

Adjusted EBITDA was $14.3 million in the nine months ended September 30, 2023, compared to $6.2 million in the nine months ended September 30, 2022.

Balance Sheet Summary

As of September 30, 2023, the Company had $66.0 million in cash and cash equivalents and $46.8 million of outstanding borrowings under its credit agreement, compared to $21.9 million in cash and cash equivalents and $49.0 million of outstanding borrowings under its credit agreement as of December 31, 2022.

2023 Financial Outlook

The Company now expects full year 2023 total revenue in the range of $273.0 million to $277.0 million, representing growth of approximately 11% to 12% year-over-year. The Company’s prior 2023 revenue guidance expectation was total revenue in the range of $274.0 million to $278.0 million, representing growth of approximately 11% to 13% year-over-year.

Conference Call

Management will host a conference call at 5:00 p.m. Eastern Time on November 6th, 2023, to discuss the results of the quarter with a question-and-answer session. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13741621. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13741621. The webcast will be archived at investors.tactilemedical.com.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the impact of inflation, rising interest rates or a recession; the adequacy of the Company’s liquidity to pursue its business objectives; the Company’s ability to obtain reimbursement from third-party payers for its products; adverse economic conditions or intense competition; price increases for supplies and components; wage and component price inflation; loss of a key supplier; entry of new competitors and products; compliance with and changes in federal, state and local government regulation; loss or retirement of key executives, including prior to identifying a successor; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; the impacts of the COVID-19 pandemic on the Company’s business, financial condition and results of operations, and the Company’s inability to mitigate such impacts; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

This press release includes the non-GAAP financial measures of Adjusted EBITDA, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income (loss), and non-GAAP net income (loss), which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”).

Adjusted EBITDA in this release represents net income or loss, plus interest expense, net, or less interest income, net, less income tax benefit or plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, plus or minus the change in fair value of earn-out, plus litigation defense costs and plus executive transition costs. Non-GAAP gross profit in this release represents gross profit plus non-cash intangible amortization expense. Non-GAAP gross margin in this release represents non-GAAP gross profit divided by revenue. Non-GAAP operating income (loss) in this release represents operating income (loss) adjusted for non-cash intangible amortization expense, change in fair value of earn-out, litigation defense costs and executive transition expenses. Non-GAAP net income (loss) represents net income (loss) adjusted for non-cash intangible amortization expense, change in fair value of earn-out, litigation defense costs and executive transition expenses, and adjusted for the income tax effect on reconciling items. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in this press release.

These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these measures principally as measures of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating plan and financial projections. The Company believes these measures are useful to investors as supplemental information and because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company also believes these non-GAAP financial measures are useful to its management and investors as a measure of comparative operating performance from period to period. In addition, Adjusted EBITDA is used as a performance metric in the Company’s compensation program.

The non-GAAP financial measures presented in this release should not be considered as an alternative to, or superior to, their respective GAAP financial measures, as measures of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and they should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating non-GAAP financial measures, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using non-GAAP financial measures on a supplemental basis. The Company’s definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

The following table summarizes revenue by product line for the three and nine months ended September 30, 2023 and 2022:

The following table contains a reconciliation of GAAP gross profit and margin to non-GAAP gross profit and margin:

The following table contains a reconciliation of GAAP operating income (loss) to non-GAAP operating income (loss):

The following table contains a reconciliation of GAAP net income (loss) to non-GAAP net income (loss):

The following table contains a reconciliation of net income (loss) to Adjusted EBITDA for the three and nine months ended September 30, 2023 and 2022, as well as the dollar and percentage change between the comparable periods:

Investor Inquiries:
Mike Piccinino, CFA
ICR Westwicke
443-213-0500
[email protected]

Source: Tactile Systems Technology, Inc.